Phosphoinositide 3-Kinase Inhibitors from Gladiolus segetum Ker-Gawl Corms Supported by Network Pharmacology.

Gladiolus segetum LC-MS Molecular dynamics simulation antiproliferative docking

Journal

Chemistry & biodiversity
ISSN: 1612-1880
Titre abrégé: Chem Biodivers
Pays: Switzerland
ID NLM: 101197449

Informations de publication

Date de publication:
13 Sep 2024
Historique:
revised: 04 09 2024
received: 26 06 2024
accepted: 09 09 2024
medline: 13 9 2024
pubmed: 13 9 2024
entrez: 13 9 2024
Statut: aheadofprint

Résumé

Gladiolus segetum Ker-Gawl corms total extract exhibited remarkable in vitro anti-proliferative effects against panel of cancer cell lines; including human colon carcinoma (Caco-2), human breast cancer (MCF7) and hepatocellular carcinoma (HepG2) cell lines with IC50 values of 7.4, 9.1 and 11.2 µg/ml, respectively. The total ethanolic extract of G. segetum Ker-Gawl corms was subjected to untargeted metabolomics profiling using LC-HR-ESI-MS, which revealed the presence of various clusters of phytoconstituents as triterpenes, anthraquinones, flavonoids and phenolic derivatives. Network pharmacology study was performed for all identified compounds, the formed networks identified 73 intersected genes. The diagrammatic illustration of the top pathways revealed that phosphoinositide 3-kinase (PI3K) gene is the effective dominant gene in the top four KEGG pathways. Upon molecular docking and molecular dynamics investigation, kaempferol-3-O-glucopyranoside was suggested to be key anticancer metabolite. Interestingly, cytotoxic investigation of this compound revealed potential activity against the tested cancer cell lines (Caco-2, MCF7 and HepG2) with IC50 values of 6.2, 8.5 and 9.3 µg/ml, respectively. The present study highlighted the potential of G. segetum Ker-Gawl as a promising source of interesting anticancer scaffolds.

Identifiants

pubmed: 39269195
doi: 10.1002/cbdv.202401457
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e202401457

Informations de copyright

© 2024 Wiley‐VCH GmbH.

Auteurs

Basma Khalaf Mahmoud (BK)

Minia University Faculty of Pharmacy, Pharmacognosy, Minia 61519, Egypt, Minia, EGYPT.

Miada F Abdelwahab (MF)

Minia University Faculty of Pharmacy, Pharmacognosy, Faculty of Pharmacy, Minia, Egypt, 61519, Minia, EGYPT.

Fatma Alzahraa Mokhtar (FA)

Al Salam University, Pharmacognosy, Kafr El Zayat 31616, Kafr El Zayat 31616, EGYPT.

Ahmed M Sayed (AM)

Nahda University, Pharmacognosy, Beni-Suef 62513, Egypt, Beni-Suef, EGYPT.

Jianye Zhang (J)

Guangzhou Medical University, School of Pharmaceutical Sciences, Guangzhou 511436, China, Guangzhou, CHINA.

Faisal Alsenani (F)

Umm Al-Qura University, Pharmacognosy, Makkah 21955, Saudi Arabia., Umm Al-Qura, SAUDI ARABIA.

Hany A M Elsherief (HAM)

Deraya University, Pharmaceutical Chemistry, 61111 New Minia, Egypt, New Minia, EGYPT.

Faisal H Altemani (FH)

University of Tabuk, Medical Laboratory Technology, Tabuk 71491, Saudi Arabia, Tabuk, SAUDI ARABIA.

Naseh A Algehainy (NA)

University of Tabuk, Medical Laboratory Technology, Tabuk 71491, Saudi Arabia, Tabuk, SAUDI ARABIA.

Leane Lehmann (L)

Universität Würzburg, Chair of Food Chemistry, Institute of Pharmacy and Food Chemistry, Am Hubland, 97074 Würzburg, Germany, Würzburg, GERMANY.

Usama Ramadan Abdelmohsen (UR)

Minia University Faculty of Pharmacy, Pharmacognosy, 61519 Minia, Egypt, 61519, Minia, EGYPT.

Adel M Abd El-Kader (AM)

Deraya University, Pharmacognosy, 61111 New Minia, Egypt, New Minia, EGYPT.

Classifications MeSH